Welcome to the Revelo Lab!
Obesity-related inflammation of tissues such as the liver and visceral adipose tissue and liver is a key factor in the development of metabolic disease. In the liver, non-alcoholic fatty liver disease (NAFLD) is associated with hepatic insulin resistance and systemic glucose dysregulation. However, the immunological factors supporting these processes are poorly understood.
Our research investigates the integrative biology of metabolic disease with emphasis on the role of the immune system on obesity and its complications.
Follow us on twitter @Xavier_Revelo
We are currently hiring for highly motivated postdoctoral fellows. Please send a CV and short cover letter to Dr. Revelo email@example.com
Our laboratory aims to better understand the pathophysiology of non-alcoholic fatty liver disease or NAFLD which is estimated to affect 30% of the population. This is critical as NAFLD is one of the leading causes of abnormal liver function with no approved therapies for its treatment.
Our current projects:
- Mechanisms of hepatic and intestinal inflammation in obesity and NAFLD
- Anti-inflammatory mechanisms of exercise in obesity and NAFLD
- Modulation of immune pathways as potential therapeutics for metabolic disease